Lau W, Leung K, Leung T W, Liew C T, Chan M S, Yu S C, Li A K
Joint Hepatocellular Carcinoma Study Group, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Ann Surg. 1997 Mar;225(3):281-5. doi: 10.1097/00000658-199703000-00007.
This prospective cohort study on patients with hepatocellular carcinoma (HCC) presenting with jaundice emphasized the importance of differentiating patients with hepatic insufficiency from patients with obstructive jaundice caused by tumor.
There are little data in the medical literature on the management of patients with HCC presenting with jaundice. Experience has accumulated mainly from case reports and retrospective studies.
Data were collected prospectively on 2095 patients with HCC seen over a 12-year period. All patients were investigated with blood tests, abdominal ultrasound, and chest radiography. Endoscopic retrograde cholangiopancreatography-percutaneous transhepatic cholangiography, computed tomography and hepatic angiography were carried out in selected patients.
Of the 530 patients who had clinically detectable jaundice, 481 had jaundice due to hepatic insufficiency and 49 patients had obstructive jaundice. Patients with hepatic insufficiency had extremely poor prognosis, and 90% of them died within 10 weeks of first presentation. "Curative" resection, however, was possible in 9 of 49 patients with obstructive jaundice, and histologic analysis showed resectional margin involvement by tumor in 1 patient. In addition, 35 patients were treated with biliary stents to relieve the obstructive jaundice. Supportive treatment only was given to five patients who were considered too terminally ill. The overall survival of patients with HCC with obstructive jaundice was similar to those patients who presented with no clinical detectable jaundice and was much better than those with jaundice due to hepatic insufficiency (log-rank test, p < 0.001).
The prognosis of patients with HCC who presented with jaundice due to hepatic insufficiency was dismal. It is important to identify the patients who had obstructive jaundice because with proper treatment, good palliation and occasional cure are possible.
这项针对出现黄疸的肝细胞癌(HCC)患者的前瞻性队列研究强调了区分肝功能不全患者与肿瘤所致梗阻性黄疸患者的重要性。
医学文献中关于出现黄疸的HCC患者管理的数据很少。经验主要来自病例报告和回顾性研究。
前瞻性收集了12年间诊治的2095例HCC患者的数据。所有患者均接受了血液检查、腹部超声和胸部X线检查。部分患者进行了内镜逆行胰胆管造影-经皮肝穿刺胆管造影、计算机断层扫描和肝血管造影。
在530例临床上可检测到黄疸的患者中,481例因肝功能不全出现黄疸,49例为梗阻性黄疸。肝功能不全的患者预后极差,其中90%在首次出现症状后的10周内死亡。然而,49例梗阻性黄疸患者中有9例可行“根治性”切除,组织学分析显示1例患者切缘有肿瘤累及。此外,35例患者接受了胆道支架置入术以缓解梗阻性黄疸。仅对5例被认为病情终末期的患者给予了支持性治疗。HCC伴梗阻性黄疸患者的总生存期与无临床可检测黄疸的患者相似,且远优于因肝功能不全出现黄疸的患者(对数秩检验,p<0.001)。
因肝功能不全出现黄疸的HCC患者预后不佳。识别出梗阻性黄疸患者很重要,因为通过适当治疗,有可能实现良好的姑息治疗甚至治愈。